Evidence map›Paper›PMID 40430299›Full record

ReviewMolecules (Basel, Switzerland)2025

Recent Developments in Penem Antibiotics: Structural and Therapeutic Perspectives.

Aura Rusu, Octavia-Laura Oancea, Elena Donici, Livia Uncu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. A systematic review of data on the resistance of uropathogens to sulopenem.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. The oral penems and carbapenems.Clinical microbiology reviews · 2025
    Review
  8. [Beta-lactams and beta-lactamase inhibitors-current developments].Innere Medizin (Heidelberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aura RusuPharmaceutical and Therapeutic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania.ORCID 0000-0003-4979-6903
Octavia-Laura OanceaOrganic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania.ORCID 0000-0002-9333-4063
Elena DoniciScientific Center for Drug Research, Pharmaceutical and Toxicological Chemistry Department, "Nicolae Testemitanu" State University of Medicine and Pharmacy, 165 Bd. Stefan Cel Mare si Sfant, MD-2004 Chisinau, Moldova.ORCID 0000-0001-6862-7449
Livia UncuScientific Center for Drug Research, Pharmaceutical and Toxicological Chemistry Department, "Nicolae Testemitanu" State University of Medicine and Pharmacy, 165 Bd. Stefan Cel Mare si Sfant, MD-2004 Chisinau, Moldova.ORCID 0000-0003-3453-2243

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review examines the latest progress of β-lactam antibiotics, focusing on penems. Penems are distinguished by their unique structural characteristics and remarkable antibacterial activity. The structural characteristics of the class that differentiate it from carbapenems or monobactams are addressed. Notable representatives such as sulopenem and faropenem are discussed. Faropenem's stability and efficacy against resistant bacterial strains emphasize the therapeutic potential of penems. The review highlights sulopenem's recent FDA approval, marking a key point in treating uncomplicated urinary tract infections caused by specific bacteria in adult women with minimal or no other options for oral antibiotic treatment. The review covers sulopenem's structural considerations, physicochemical properties, mechanisms of action, antibacterial activity, and clinical pharmacology. The development of penem derivatives is also addressed, emphasizing their potential in combating resistant bacterial infections. Despite having few approved representatives, penems show promising prospects for future design and may significantly contribute to the fight against bacterial resistance. The review also highlights the challenges and future possibilities in penem research, including the need for improved oral bioavailability and the potential for combination therapies with β-lactamase inhibitors. Overall, penems are valuable antibacterial agents in the antimicrobial arsenal, offering hope in the ongoing battle against multidrug-resistant pathogens.

Indexed as

Anti-Bacterial Agentsbeta-LactamsAnimalsBacterial InfectionsHumansAnti-Bacterial Agentsbeta-Lactamsantibacterial activityantibacterial resistancecarbapenemsfaropenempenem derivativespenemssulopenemurinary tract infections (UTIs)β-lactam antibioticsβ-lactamase inhibitors

Identifiers

PMID40430299
PMCPMC12113772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.